Adding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinoma

Basit Öğe Kaydı
dc.authoridKose, Mehmet Faruk/0000-0001-6136-5597
dc.authoridGulkesen, Kemal Hakan/0000-0002-2477-2481
dc.authoridTulunay, Gokhan/0000-0003-0440-0725
dc.authorwosidAdli, Mustafa/ABH-5809-2020
dc.authorwosidKose, Mehmet Faruk/ABE-9977-2021
dc.authorwosidGulkesen, Kemal Hakan/C-1584-2016
dc.authorwosidGulkesen, Kemal Hakan/ABD-1376-2021
dc.contributor.authorGaripagaoglu, M
dc.contributor.authorKayikçioglu, F
dc.contributor.authorKöse, MF
dc.contributor.authorAdli, M
dc.contributor.authorGülkesen, KH
dc.contributor.authorKoçak, Z
dc.contributor.authorTulunay, G
dc.date.accessioned2024-06-12T11:20:00Z
dc.date.available2024-06-12T11:20:00Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe tolerability and efficacy of the continuous infusion of cisplatin during radiotherapy was studied by tumour response, survival and pelvic control, in carcinoma of the cervix. 44 patients with stage IIB-IIIB cervical carcinoma were prospectively randomized into two groups: radiation alone (control group) versus radiation plus cisplatin (study group). While there was no significant difference in diarrhoea and urinary complication scores, emesis and appetite changes were significantly greater in the study group. Tumour responses were no different at the end of the treatment and 3 months after completion of treatment. After 40 months median follow-up, 40/44 patients were assessed (one had a second primary tumour and three were lost to follow-up). Persistent disease was found in 3 patients: one in the study arm and two in the control arm. Recurrence was seen in 10 patients in the first 2 years. 5-year pelvic control rates were; 69.41/0 and 63.91/0 (p = 0.7), survival rates were 52.0% and 48.9% (p = 0.7) and disease-free survival rates were 67.5% and 58.7% (p = 0.3) for the control and the study groups, respectively. Although the continuous infusion of cisplatin during radiotherapy was well tolerated, this additional treatment did not appear to show an improvement in pelvic control, survival, or disease-free survival.en_US
dc.identifier.doi10.1259/bjr/63967203
dc.identifier.endpage587en_US
dc.identifier.issn0007-1285
dc.identifier.issue919en_US
dc.identifier.pmid15238405en_US
dc.identifier.scopus2-s2.0-4344659420en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage581en_US
dc.identifier.urihttps://doi.org/10.1259/bjr/63967203
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25418
dc.identifier.volume77en_US
dc.identifier.wosWOS:000222993100008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBritish Inst Radiologyen_US
dc.relation.ispartofBritish Journal Of Radiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSquamous-Cell Carcinomaen_US
dc.subjectGynecologic-Oncology-Groupen_US
dc.subjectPelvic Radiation-Therapyen_US
dc.subjectStage-Iiib Carcinomaen_US
dc.subjectTerm Follow-Upen_US
dc.subjectUterine Cervixen_US
dc.subjectRadical Radiotherapyen_US
dc.subjectRate Brachytherapyen_US
dc.subjectAdvanced Canceren_US
dc.subjectTreatment Timeen_US
dc.titleAdding concurrent low dose continuous infusion of cisplatin to radiotherapy in locally advanced cervical carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu